acetoxime has been researched along with Glioblastoma in 1 studies
*Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boucher, P; Chiocca, EA; Finkelberg, T; Jimenez-Macias, JL; Koch, MS; Lawler, SE; Li, W; Ling, AL; Manz, KE; Nowicki, MO; Pennell, KD; Piranlioglu, R; Takeda, Y; Wu, B; Zdioruk, M | 1 |
1 other study(ies) available for acetoxime and Glioblastoma
| Article | Year |
|---|---|
PPRX-1701, a nanoparticle formulation of 6'-bromoindirubin acetoxime, improves delivery and shows efficacy in preclinical GBM models.
Topics: Animals; Glioblastoma; Kynurenine; Mice; Oximes; Tryptophan | 2023 |